The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
作者信息
Racil Zdenek, Razga Filip, Buresova Lucie, Jurcek Tomas, Dvorakova Dana, Zackova Daniela, Timilsina Shira, Cetkovsky Petr, Mayer Jiri
出版信息
Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722.
Abstract
摘要
相似文献
1
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722.
2
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
Blood. 2013 Jan 24;121(4):628-37. doi: 10.1182/blood-2012-01-405035. Epub 2012 Dec 5.
3
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Blood. 2008 Oct 15;112(8):3348-54. doi: 10.1182/blood-2007-10-116236. Epub 2008 Jul 31.
4
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
Blood. 2013 Jun 13;121(24):4965-6. doi: 10.1182/blood-2013-03-493841.
5
[Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients].
Zhonghua Xue Ye Xue Za Zhi. 2009 Sep;30(9):596-600.
6
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.
Leuk Lymphoma. 2008 Apr;49(4):639-42. doi: 10.1080/10428190701858823.
7
[Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
Zhonghua Yi Xue Za Zhi. 2012 May 29;92(20):1405-8.
8
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Leuk Lymphoma. 2002 Dec;43(12):2281-9. doi: 10.1080/1042819021000039992.
9
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6.
10
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
Pharmacogenomics J. 2014 Aug;14(4):328-35. doi: 10.1038/tpj.2014.7. Epub 2014 Mar 4.
引用本文的文献
1
Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic.
Haematologica. 2017 Jan;102(1):e31-e32. doi: 10.3324/haematol.2016.157065.
2
Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?
Leukemia. 2017 Jan;31(1):266-267. doi: 10.1038/leu.2016.266. Epub 2016 Oct 21.
3
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8.
4
OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.
Haematologica. 2011 Feb;96(2):213-20. doi: 10.3324/haematol.2010.033290. Epub 2010 Oct 22.
本文引用的文献
1
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30.
2
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Clin Pharmacol Ther. 2008 Feb;83(2):258-64. doi: 10.1038/sj.clpt.6100268. Epub 2007 Jun 13.
3
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Leukemia. 2007 May;21(5):926-35. doi: 10.1038/sj.leu.2404609. Epub 2007 Mar 1.
4
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
Blood. 2006 Jul 15;108(2):697-704. doi: 10.1182/blood-2005-11-4687. Epub 2006 Apr 4.
5
hOCT 1 and resistance to imatinib.
Blood. 2005 Aug 1;106(3):1133-4; author reply 1134. doi: 10.1182/blood-2005-02-0694.
6
Active transport of imatinib into and out of cells: implications for drug resistance.
Blood. 2004 Dec 1;104(12):3739-45. doi: 10.1182/blood-2003-12-4276. Epub 2004 Aug 17.
7
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
Leukemia. 2003 Dec;17(12):2318-57. doi: 10.1038/sj.leu.2403135.
8
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.
Leukemia. 2003 Dec;17(12):2474-86. doi: 10.1038/sj.leu.2403136.
Zotero 插件